The Gold Standard is a workplace- based program that focuses on lowering the risk of cancer.
Visit Website

The Life Sciences Consortium (LSC) brings together oncology companies to accelerate discovery and development of new therapies for all cancer patients. Visit Website

Task Forces at a Glance

The CEO Cancer Gold Standard™ created by the Member CEOs in 2004, is a comprehensive, workplace-based initiative that encourages state-of-the-science prevention, early diagnosis and quality treatment. The Gold Standard addresses three specific goals:

  • Risk Reduction, reducing the risk for cancer,
  • Early Detection, when detecting it at the earliest possible stage can improve outcomes, and
  • Quality Care, ensuring access to high-quality treatment, including participation in clinical trials.

The focus is in five critical areas, referred to as “Pillars”, and they are aligned with the three major goals:

Risk Reduction

  • Tobacco Use
  • Nutrition
  • Physical Activity

Early Detection

  • Prevention, Screening & Early Detection

Quality Care

  • Access to Quality Treatment & Clinical Trials

For each Pillar, organizations that adopt the Gold Standard maintain a culture that encourages healthy lifestyles and provides support when a diagnosis of cancer becomes a reality. In addition, they offer benefits and programming that lower the risk of cancer, detect it earlier, and provide access to the best-available care. Organizations that become accredited as “CEO Cancer Gold Standard™ employers” must satisfy the requirements of all five pillars. Please visit www.cancergoldstandard.com for much more information about the Gold Standard, including how to apply for accreditation.


The Life Sciences Consortium (LSC) was formed in 2005 by the CEO Roundtable on Cancer as a means of bringing together leading oncology pharmaceutical/biotechnology companies to build collaboration in cancer drug development. The goal of these collaborations is a transformation in research and development that will effectively deliver new agents to prevent and treat cancer to people who need them and fulfill the promise of our emerging understanding of cancer biology. This collaboration focuses on exploring and solving issues common to all cancer companies engaged in drug discovery and development that cannot be solved by any company alone. Please visit www.ceo-lsc.org for much more information about the Life Sciences Consortium and its progress.